Sangamo Therapeutics Inc. held its annual meeting of stockholders on June 12, 2025. During the meeting, stockholders approved the election of nine directors to the board. The amendment and restatement of the 2018 Equity Incentive Plan was also approved, increasing the number of shares available under the plan. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.